accessibility adapter TM

Font Adjustments

Contrast

Cursor and Zoom

Display Adjustments
ADA Site Compliance Logo

Powered By ADA Site Compliance
Terms and Conditions

Skip to content
FIRST Kits UNIT-OF-USE-PRESCRIPTION COMPOUNDING KITS Logo
  • Home
  • Products
    • Omeprazole
    • Lansoprazole
    • Metronidazole
    • Mouthwash BLM
  • Product FAQs
  • Contact Us

Home > WILMINGTON, Mass. (Jan. 15, 2019) – CutisPharma, Inc. announced today the appointments of Mike Radice as Chief Commercial Officer, Chief Financial Officer Ron Scarboro’s expanded role as Chief Operating Officer, and Hanok George as General Counsel.

WILMINGTON, Mass. (Jan. 15, 2019) – CutisPharma, Inc. announced today the appointments of Mike Radice as Chief Commercial Officer, Chief Financial Officer Ron Scarboro’s expanded role as Chief Operating Officer, and Hanok George as General Counsel.

January 15, 2019

Share this Story

  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Digg
  • Delicious
  • Google++
  • E-Mail+

Leave a reply

Cancel reply

Your email address will not be published. Required fields are marked *

Prev Post
Next Post
  • Terms of Use
  • Privacy Policy and Cookie Notice
  • Web Accessibility Policy

The Information contained herein, including product information, is intended only for residents of the United States.

©2025 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners.

PP-FKS-US-0119

FIRST Kits unit of use prescription compunding kits logo Web Accessibility Policy
  • Azurity Pharmaceuticals Logo
Back to Top
  • Home
  • Products
    ▼
    • Omeprazole
    • Lansoprazole
    • Metronidazole
    • Mouthwash BLM
  • Product FAQs
  • Contact Us

Learn More About FIRSTKIT®

Learn more about how FIRSTKIT may benefit your patients.

*Fields are required.

Terms and conditions

By clicking Submit, you agree to receive product and disease state information from Azurity Pharmaceuticals, Inc. All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

I Accept(Required)

†Terms and Conditions must be accepted before submission.

Sign Up for Email Updates

Share your email to receive information about FIRSTKIT® and new hypothyroidism resources.

*Fields are required

Terms and conditions

By clicking Submit, you agree to receive product and disease state information from Azurity

All personal information will be kept confidential and will not be shared with any parties other than Azurity Pharmaceuticals, Inc. and Spectrum Science Communications, Inc.

I accept(Required)

†Terms and Conditions must be accepted before submission.

Notifications